Stopping tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia who have achieved deep molecular response could help reduce health expenditure.
Older age, African American race, and low socioeconomic status may be linked with a reduced likelihood of receiving multiple myeloma treatment of any kind.
For patients with cancer or multiple serious comorbidities, consulting with a palliative care team within 3 days of hospital admission may significantly reduce hospital costs.
A comparative effectiveness study examined clinical outcomes and costs after treatment with a febrile neutropenia therapy vs a biosimilar for patients with non-myeloid cancer undergoing chemotherapy.
Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization.
A recent study analyzed the effects of implementing a clinical pathway for thyroid cancer in a hospital setting.
A JAMA Oncology research letter sheds light on the average additional costs associated with CAR-T therapy, which can be from $30,000 to $36,000 per patient.
A new economic model may help clinicians and payers have a better understanding of the relative clinical benefits and costs of second-line treatment options for metastatic renal cell carcinoma.
A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma.
A recent study demonstrated the real-world effectiveness and tolerability of a targeted agent for the treatment of relapsed or refractory mantle cell lymphoma.